OC
BBIO icon

Oppenheimer & Co’s BridgeBio Pharma BBIO Stock Holding History

Oppenheimer & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$517K Buy
6,945
+6
+0.1% +$420 0.01% 1242
2026
Q1 		$515K Hold
6,939
– – 0.01% 1178
2025
Q4 		$531K Sell
6,939
-906
-12% -$59.5K 0.01% 1059
2025
Q3 		$407K Buy
+7,845
New +$383K 0.01% 1259

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Oppenheimer & Co's BBIO Position: Q2 2026 in Review

Oppenheimer & Co increased its BridgeBio Pharma (BBIO) stake by 0.09% in Q2 2026, buying an estimated $420 and bringing the position to 6,945 shares worth $517K. The position accounts for 0.01% of the portfolio, ranked #1242.

Oppenheimer & Co first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $531K in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Oppenheimer & Co held 6,945 shares of BridgeBio Pharma worth $517K as of Q2 2026.
  • Oppenheimer & Co bought 6 BridgeBio Pharma shares in Q2 2026, an estimated $420.
  • BridgeBio Pharma made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1242 holding.
  • Oppenheimer & Co first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Oppenheimer & Co's BridgeBio Pharma position peaked at $531K in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.